Cloud-native molecular design platform for drug discovery
OpenEye builds Orion, a cloud-based computational chemistry platform for pharma and biotech R&D. The tech stack—Vue, Nuxt, Next.js, WebGL, WebAssembly, C++, Python on AWS—reflects a frontend-heavy, visualization-first architecture optimized for 3D molecular rendering and interactive analysis. Active projects span UI modernization, molecular dynamics simulation, and cryptic pocket detection workflows, while repeated mentions of modernizing legacy systems suggest the team is actively rebuilding core components to scale computational workloads in the cloud.
OpenEye, acquired by Cadence Design Systems in 2022, specializes in computational tools for molecular design and drug discovery. The company has operated for over 25 years and serves pharma and biotech organizations worldwide, with offices in Santa Fe, Boston, Cologne, and Tokyo. Orion consolidates shape and electrostatics analysis, virtual screening, free energy calculations, and molecular dynamics simulation into a single SaaS platform. The focus is on enabling scientists to visualize, analyze, and optimize small-molecule structures at scale using cloud infrastructure.
Vue, Nuxt, Next.js, JavaScript, TypeScript, Python, C++, WebGL, WebAssembly, and AWS. The stack emphasizes browser-based 3D visualization and computational chemistry workloads.
Yes. Active roles span engineering, with positions posted in the United States, United Kingdom, and India across intern, mid, and principal levels.
Santa Fe, New Mexico. The company also maintains offices in Boston, Cologne, and Tokyo.
Other companies in the same industry, closest in size